Capital Group Private Client Services, Inc. Bei Gene, Ltd. Transaction History
Capital Group Private Client Services, Inc.
- $5.15 Billion
- Q3 2025
A detailed history of Capital Group Private Client Services, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Capital Group Private Client Services, Inc. holds 43,728 shares of BGNE stock, worth $9.91 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
43,728
Previous 148,613
70.58%
Holding current value
$9.91 Million
Previous $33.7 Million
70.58%
% of portfolio
0.19%
Previous 0.32%
Shares
17 transactions
Others Institutions Holding BGNE
# of Institutions
297Shares Held
30.4MCall Options Held
147KPut Options Held
195K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion16.25% of portfolio
-
Primecap Management CO Pasadena, CA5.08MShares$1.15 Billion0.91% of portfolio
-
Capital International Investors Los Angeles, CA5.05MShares$1.14 Billion0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.63MShares$370 Million0.06% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million7.05% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...